Imugene Limited (IUGNF)
USD 0.02
(-23.91%)
USD 0.02
(-23.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -91.56 Million AUD | 38.98% |
| 2023 | -152.59 Million AUD | -53.81% |
| 2022 | -99.21 Million AUD | -239.59% |
| 2021 | -29.21 Million AUD | 2.73% |
| 2020 | -30.03 Million AUD | -58.72% |
| 2019 | -18.92 Million AUD | -141.94% |
| 2018 | -7.82 Million AUD | -62.48% |
| 2017 | -4.81 Million AUD | -204.2% |
| 2016 | -1.58 Million AUD | 19.13% |
| 2015 | -1.95 Million AUD | -60.03% |
| 2014 | -1.22 Million AUD | -116.2% |
| 2013 | -565.62 Thousand AUD | 44.37% |
| 2012 | -1.01 Million AUD | 46.65% |
| 2011 | -1.9 Million AUD | -140.33% |
| 2010 | -793.06 Thousand AUD | 68.12% |
| 2009 | -2.48 Million AUD | -53.57% |
| 2008 | -1.61 Million AUD | -47.35% |
| 2007 | -1.09 Million AUD | 59.25% |
| 2006 | -2.69 Million AUD | 37.94% |
| 2005 | -4.34 Million AUD | -351.46% |
| 2004 | -962.74 Thousand AUD | 63.22% |
| 2003 | -2.61 Million AUD | -234.33% |
| 2002 | -783 Thousand AUD | -165.97% |
| 2001 | 1.18 Million AUD | 1114.46% |
| 2000 | -117 Thousand AUD | 93.73% |
| 1999 | -1.86 Million AUD | -54.3% |
| 1998 | -1.21 Million AUD | 17.74% |
| 1997 | -1.47 Million AUD | -206.44% |
| 1996 | 1.38 Million AUD | 269.52% |
| 1995 | 374 Thousand AUD | 106.77% |
| 1994 | -5.52 Million AUD | -12946.51% |
| 1993 | 43 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -135.21 Million AUD | 0.0% |
| 2024 Q4 | -91.56 Million AUD | 0.0% |
| 2024 FY | -91.56 Million AUD | 40.0% |
| 2024 Q1 | -135.21 Million AUD | -36.28% |
| 2023 Q1 | -161.9 Million AUD | -63.19% |
| 2023 Q4 | -99.21 Million AUD | 35.06% |
| 2023 FY | -152.59 Million AUD | -53.81% |
| 2023 Q3 | -152.78 Million AUD | 5.38% |
| 2023 Q2 | -161.48 Million AUD | 0.26% |
| 2022 Q3 | -99.39 Million AUD | 16.05% |
| 2022 FY | -99.21 Million AUD | -239.59% |
| 2022 Q1 | -118.4 Million AUD | -305.28% |
| 2022 Q2 | -118.4 Million AUD | 0.0% |
| 2022 Q4 | -99.21 Million AUD | 0.19% |
| 2021 Q1 | -32.83 Million AUD | -9.31% |
| 2021 Q4 | -29.21 Million AUD | 0.36% |
| 2021 FY | -29.21 Million AUD | 2.73% |
| 2021 Q2 | -32.83 Million AUD | 0.0% |
| 2021 Q3 | -29.32 Million AUD | 10.69% |
| 2020 Q3 | -30.09 Million AUD | 18.06% |
| 2020 FY | -30.03 Million AUD | -58.72% |
| 2020 Q1 | -36.73 Million AUD | -94.08% |
| 2020 Q2 | -36.73 Million AUD | 0.0% |
| 2020 Q4 | -30.03 Million AUD | 0.2% |
| 2019 Q2 | -23.95 Million AUD | 0.0% |
| 2019 FY | -18.92 Million AUD | -141.94% |
| 2019 Q1 | -23.95 Million AUD | -206.29% |
| 2019 Q4 | -18.92 Million AUD | 0.31% |
| 2019 Q3 | -18.98 Million AUD | 20.76% |
| 2018 Q1 | -11.92 Million AUD | -147.68% |
| 2018 FY | -7.82 Million AUD | -62.48% |
| 2018 Q4 | -7.82 Million AUD | 0.0% |
| 2018 Q3 | -7.82 Million AUD | 34.4% |
| 2018 Q2 | -11.92 Million AUD | 0.0% |
| 2017 Q2 | -3.82 Million AUD | 0.0% |
| 2017 Q4 | -4.81 Million AUD | 0.0% |
| 2017 Q3 | -4.81 Million AUD | -25.85% |
| 2017 FY | -4.81 Million AUD | -204.2% |
| 2017 Q1 | -3.82 Million AUD | -141.72% |
| 2016 Q1 | -3.72 Million AUD | -90.33% |
| 2016 Q2 | -3.72 Million AUD | 0.0% |
| 2016 Q4 | -1.58 Million AUD | 0.0% |
| 2016 FY | -1.58 Million AUD | 19.13% |
| 2016 Q3 | -1.58 Million AUD | 57.51% |
| 2015 Q1 | -2.99 Million AUD | -144.86% |
| 2015 Q4 | -1.95 Million AUD | 0.0% |
| 2015 Q3 | -1.95 Million AUD | 34.64% |
| 2015 FY | -1.95 Million AUD | -60.03% |
| 2015 Q2 | -2.99 Million AUD | 0.0% |
| 2014 Q3 | -1.22 Million AUD | 50.38% |
| 2014 FY | -1.22 Million AUD | -116.2% |
| 2014 Q1 | -2.46 Million AUD | -335.75% |
| 2014 Q2 | -2.46 Million AUD | 0.0% |
| 2014 Q4 | -1.22 Million AUD | 0.0% |
| 2013 Q3 | -565.62 Thousand AUD | 0.0% |
| 2013 FY | -565.62 Thousand AUD | 44.37% |
| 2013 Q4 | -565.62 Thousand AUD | 0.0% |
| 2012 Q4 | -1.01 Million AUD | 0.0% |
| 2012 FY | -1.01 Million AUD | 46.65% |
| 2011 Q4 | -1.9 Million AUD | 0.0% |
| 2011 FY | -1.9 Million AUD | -140.33% |
| 2010 FY | -793.06 Thousand AUD | 68.12% |
| 2010 Q4 | -793.06 Thousand AUD | 0.0% |
| 2009 Q4 | -2.48 Million AUD | 0.0% |
| 2009 FY | -2.48 Million AUD | -53.57% |
| 2008 Q4 | -1.61 Million AUD | 0.0% |
| 2008 FY | -1.61 Million AUD | -47.35% |
| 2007 Q4 | -1.09 Million AUD | 0.0% |
| 2007 FY | -1.09 Million AUD | 59.25% |
| 2006 Q4 | -2.69 Million AUD | 0.0% |
| 2006 FY | -2.69 Million AUD | 37.94% |
| 2005 FY | -4.34 Million AUD | -351.46% |
| 2005 Q4 | -4.34 Million AUD | 0.0% |
| 2004 FY | -962.74 Thousand AUD | 63.22% |
| 2004 Q4 | -962.74 Thousand AUD | 0.0% |
| 2003 Q4 | -2.61 Million AUD | 0.0% |
| 2003 FY | -2.61 Million AUD | -234.33% |
| 2002 FY | -783 Thousand AUD | -165.97% |
| 2002 Q4 | -782.96 Thousand AUD | 0.0% |
| 2001 FY | 1.18 Million AUD | 1114.46% |
| 2001 Q4 | 1.18 Million AUD | 0.0% |
| 2000 Q4 | -116.71 Thousand AUD | 0.0% |
| 2000 FY | -117 Thousand AUD | 93.73% |
| 1999 Q4 | -1.86 Million AUD | 0.0% |
| 1999 FY | -1.86 Million AUD | -54.3% |
| 1998 FY | -1.21 Million AUD | 17.74% |
| 1997 Q4 | -1.47 Million AUD | 0.0% |
| 1997 FY | -1.47 Million AUD | -206.44% |
| 1996 FY | 1.38 Million AUD | 269.52% |
| 1995 FY | 374 Thousand AUD | 106.77% |
| 1994 FY | -5.52 Million AUD | -12946.51% |
| 1993 FY | 43 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 4921.736% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 680.858% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 22884.83% |
| SQZ Biotechnologies Company | -36.23 Million USD | -152.665% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 4183.457% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 313.962% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -1352.3% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 9975.107% |
| Marizyme, Inc. | 18.56 Million USD | 593.082% |
| Genus plc | 190.6 Million USD | 148.038% |
| Pharming Group N.V. | 109.8 Million USD | 183.385% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 10743.6% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 7642.756% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 13564.796% |
| ContraFect Corporation | -6.02 Million USD | -1419.426% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 8024.382% |
| IMV Inc. | 7.67 Million USD | 1293.669% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 1764.165% |
| ONE Bio Corp. | 9.04 Million USD | 1112.835% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 807.25% |
| Mesoblast Limited | 55.85 Million USD | 263.916% |
| MultiCell Technologies, Inc. | 90.04 USD | 101688917.192% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 399.668% |
| Genscript Biotech Corporation | -1.06 Billion USD | 91.373% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 14811.746% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 9185.954% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 2323.411% |
| Biomind Labs Inc. | 711.4 Thousand USD | 12970.446% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 4679.423% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 814.949% |
| Skye Bioscience, Inc. | -5.72 Million USD | -1500.321% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 25554.008% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 4195.147% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 65592.125% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 68104.524% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 1721.009% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 460967.826% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -12374.572% |
| EV Biologics, Inc. | 1.36 Million USD | 6793.169% |
| Q BioMed Inc. | 4.06 Million USD | 2355.183% |
| GB Sciences, Inc. | 1.74 Million USD | 5340.072% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -49718.601% |
| CSL Limited | 10.52 Billion USD | 100.87% |
| Agentix Corp. | 37.63 Thousand USD | 243411.661% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 251.225% |
| Enzolytics Inc. | 981.65 Thousand USD | 9427.158% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 1519.324% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -13503.047% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 4258.102% |
| argenx SE | -2.02 Billion USD | 95.487% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 310.804% |
| HST Global, Inc. | 96.79 Thousand USD | 94694.249% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -94.76% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 44500.128% |
| Halberd Corporation | 144.72 Thousand USD | 63366.983% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 1394.88% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -935.764% |
| Zenith Capital Corp. | 10.06 Thousand USD | 909883.496% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 3480.348% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 3937.356% |
| AVAX Technologies, Inc. | -5.9 Million USD | -1451.032% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 55756.901% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -499739.562% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 45781.633% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 4302.987% |
| Helix BioMedix, Inc. | -2.57 Million USD | -3462.625% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 551.571% |
| Kadimastem Ltd | -253.1 Thousand USD | -36075.38% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 2147.415% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 45595.052% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -6989259.618% |
| LadRx Corporation | -2.03 Million USD | -4396.047% |
| Cell Source, Inc. | 9.23 Million USD | 1091.777% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -448550.583% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 14515.203% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 14515.203% |
| Affymax, Inc. | -5.59 Million USD | -1535.887% |
| Mobile Lads Corp. | 484.23 Thousand USD | 19008.418% |
| Itoco Inc. | 228.3 Thousand USD | 40204.514% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 67429.424% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 1947.097% |
| International Stem Cell Corporation | 2.59 Million USD | 3635.159% |
| CytoDyn Inc. | 20.26 Million USD | 551.883% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -14151462.751% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -987785.759% |
| Qrons Inc. | 351.42 Thousand USD | 26153.949% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 1288.173% |
| SYBLEU INC | 473.71 Thousand USD | 19428.247% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -36579.998% |
| Rebus Holdings, Inc. | 305 Thousand USD | 30119.872% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 2154.3% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 146801.186% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 4298.295% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 2766.296% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 1170.509% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 11950.865% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -7224.849% |
| Neutra Corp. | 52.18 Thousand USD | 175547.163% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -3578.61% |
| PureTech Health plc | -167.19 Million USD | 45.238% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -37285.717% |
| IXICO plc | -4.44 Million USD | -1960.048% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 792.644% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 266.926% |
| CSL Limited | 10.52 Billion USD | 100.87% |
| Cellectis S.A. | -43.81 Million USD | -108.952% |